Fusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Fusidic acid, given at a dose of 250 mg twice daily, is safe and effective in the treatment of skin and soft tissue infections. The cost analysis stressed no conclusive evidence that either treatment offers significant cost-advantages.